News

Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
STAT25m
Eli Lilly’s much-anticipated obesity pill yields modest results
Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...
Lilly: Q2 Earnings Snapshot
Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The ...
Fierce Biotech56m
Lilly preps oral GLP-1 for regulatory review after phase 3 shows 12% weight loss
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...
Jim Cramer Shows Concerns That Eli Lilly “Might Be a Little Diluted”
Eli Lilly and Company (NYSE:LLY) is one of the stocks in Jim Cramer’s game plan for this week. Cramer highlighted that his ...
The Daily Reporter12h
Eli Lilly and Co. could get $100 million in state tax credits
Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin ...
Eli Lilly and Co (LLY) Traded Lower in Q2 Despite Good Results
Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...
PharmTech1d
Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease
Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...